Novo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheimer’s progression in trials. Shares hit a four-year low, continuing a downward trend amid market competition and earlier guidance cuts, raising concerns for investors.
